KR20180120120A - Composition for skin anti-aging or moisturization comprising extract of marian plum - Google Patents

Abstract

The present invention relates to a novel use of Marian plum. A Marian plum extract according to the present invention can inhibit collagenolytic enzymes, promote collagen production to enhance skin anti-aging, promote differentiation of keratinocytes and enhance skin moisturization. Therefore, the Marian plum extract can be provided as a cosmetic, a medicinal, a quasi-drug, a food or a health functional food for preventing, alleviating or treating skin aging, wrinkles of skin, lowering of elasticity, and lowering of moisture in skin.

Description

TECHNICAL FIELD The present invention relates to a composition for skin aging and moisturizing, which comprises an extract of Marian plum as an active ingredient,

The present invention relates to novel uses of marian plum, and more particularly to a composition for skin aging and skin moisturizing comprising Marian plum extract.

Skin protects the organs in the body from external stimuli and plays an important role in the maintenance of body homeostasis, such as body temperature control. These ages are accompanied by external deformations such as skin elasticity reduction, skin color change, and skin wrinkle formation as the aging progresses. These skin aging processes are manifested by the combined action of intrinsic aging or natural aging that occurs naturally as they get older, and the surrounding environment, especially ultraviolet (UV) photoaging, which is extrinsic aging. Although there is a detailed difference in the mechanism of wrinkle formation between the two aging processes, the epidermal cell proliferation and metabolism of the skin are reduced, the epidermis-dermis bond is weak and the skin is easily damaged by small stimulation, The physiological changes such as increased expression of collagen degrading enzyme MMPs (Matrix Metalloproteinases) appear and the skin becomes dry. Due to the structural change of the epidermis and dermis layer, the skin loses its elasticity and appears to be stretched and gradually becomes wrinkled. Even if the natural aging phenomenon is inevitable in the skin aging phenomenon, effectively blocking the photoaging by the ultraviolet ray which is an environmental factor is a method of delaying and suppressing the aging of the skin.

Recently, the destruction of the ozone layer due to environmental pollution has increased the amount of ultraviolet rays, and accordingly, research on photoaging has attracted attention (Dermatology and Therapy, 23 (1): 31-47, 2010). In the photoaged skin, appearance characteristics such as roughness, elastic loss, and wrinkling are observed. Among them, the main research field of photoaging is the change of the skin wrinkles. There have been many reports on the basic physiological metabolism changes such as synthesis, degradation, and moisture content of collagen, which is a major constituent of skin, in the formation of skin wrinkles by the photoaging (Annals of the New York Academy of Sciences Sciences, 973: 31-43, 2002).

Collagen in the dermal layer of the skin occupies about 70-80% of the total dry weight of the skin and it is known to control the elasticity of the skin along with the elastic fiber elastin. Particularly, ultraviolet rays increase the production of reactive oxygen species, collapse of enzymatic and non-enzymatic antioxidant defenses of skin, decrease collagen decomposition and biosynthesis, and collagen in the dermis is remarkably reduced (Journal of Investigative Dermatology, 126 (12): 2565-2575, 2006). Matrix metalloproteinases (MMPs), which are important for collagen reduction, are involved in the degradation of extracellular matrix and basement membrane. The enzyme has been reported to increase activity by ultraviolet rays and to inhibit it, thereby increasing skin thickness and wrinkling induced by ultraviolet rays (Journal of Investigative Dermatology, 120 (1): 128-134, 2003) . Therefore, it is an effective method to control MMP for prevention and treatment of photoaging.

The stratum corneum is present in the outermost layer of the skin and is directly in contact with the external environment and is responsible for barrier functions important for protecting our body from external physical and chemical stresses. This barrier function is maintained by the homeostasis of the epidermis. Epidermal homeostasis maintains a continuous skin barrier function by terminal differentiation through formation of keratinocytes in the basal layer and differentiation according to cell migration to form a skin barrier called the stratum corneum (Korean Journal of Food Science and Technology, 43: 458-463, 2011).

As keratinocytes differentiate, they produce two factors that affect moisturization. First, during keratinocyte differentiation, the cell membrane is replaced by a structure called cornified envelope. The keratinous membrane is a membrane structure in which various structural proteins including loricrin (LOR), involucrin (INV) and filaggrin (FLG) are cross-linked by an enzyme called transglutaminases (TGM) Thereby suppressing moisture evaporation in the cells. The keratinocyte structural proteins and TGMs are expressed as differentiation markers since they are expressed upon differentiation of keratinocytes (Nature Reviews Molecular Cell Biology, 6 (4): 328-340, 2005). Therefore, keratinous membrane and differentiation factor are used as an index of moisturizing. In addition, keratinocytes during the keratinocyte differentiation process have a function as a skin barrier while generating a natural moisturizing factor (NMF). FLG is a protein that is an important source for the generation of natural moisturizing factors, and FLG is decomposed into hydrophilic amino acids by caspase 14 to form a natural moisturizing factor. Natural moisturizing factors function to maintain moisture in the skin by providing water holding capacity and moisture absorption in the atmosphere (Journal of Cell Science, 122: 1285-1294, 2009). Therefore, maintaining a proper level of natural moisturizing factor on skin is a very important factor for skin health through skin barrier function. Second, the keratinocyte lipid constituting the stratum corneum of the skin is composed of lipid components such as ceramide, cholesterol, and free fatty acid. Ceramide, a type of sphingolipid, is an essential component of the structure of the stratum corneum that functions as a skin barrier, because it accounts for more than 40% of the intercellular lipid. Ceramide synthase (CerS) is the most important enzyme for ceramide synthesis, and most of the ceramide present in the stratum corneum is synthesized by CerS3 (Biochimie, 91; 784-790, 2009; Biochimica et Biophysica Acta, 1841; -434, 2014).

The tropical plant Marian Plum collectively refers to the plants whose scientific names are Bouea macrophylla and Bouea oppositifolia , Marian plum in maprang in Thailand, Gandaria in Indonesia gandaria, and kundang in Malaysia. Marian plum pulp is used in pickles, juices, jams, syrups, stews, and young leaves are used as raw materials for salads and pastes (Edible Medicinal and Non-Medicinal Plants, 1: 69-74, 2012). In addition, marienplum has been shown to have a beneficial effect on free radical elimination (Journal of Ethnopharmacology, 123: 475-482, 2009), anticancer effects (Srinagarind Medical Journal, 28 (1): 100-109, 2013) Ilmiah Farmasi, 2 (2): 1-7, 2013).

However, prior to the present invention, there has been no report on the skin anti-aging effect and moisturizing effect of promoting skin collagen synthesis and collagen degradation inhibition of Marian plum.

Accordingly, the inventors of the present invention have searched for a substance having an effect of preventing skin aging, wrinkling of skin, lowering of elasticity, prevention of moisture degradation, improvement or treatment of skin derived from natural products, and as a result, Marian plum extract has excellent skin aging and skin moisturizing activity The present invention has been completed by confirming that it has a function of preventing, ameliorating or treating skin aging, wrinkles of skin, lowering of elasticity, and lowering of moisture in skin.

Accordingly, an object of the present invention is to provide a cosmetic composition comprising Marian plum extract as an active ingredient and preventing or improving at least one member selected from the group consisting of skin wrinkles, reduced elasticity, reduced skin moisture content, and skin aging .

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin damage diseases caused by ultraviolet rays comprising Marian plum extract as an active ingredient.

Another object of the present invention is to provide a food composition comprising Marian plum extract as an active ingredient and preventing or improving at least one selected from the group consisting of skin wrinkles, elasticity reduction, skin moisture content reduction and skin aging .

Another object of the present invention is to provide a health functional food composition comprising a plant composition according to the present invention and preventing or improving at least one selected from the group consisting of skin wrinkles, .

Yet another object of the present invention is to provide a quasi-drug composition comprising marijuana extract as an active ingredient and preventing or improving at least one selected from the group consisting of skin wrinkles, skin elasticity, skin moisture content reduction and skin aging .

In order to achieve the above object, the present invention is characterized by comprising Marian plum extract as an active ingredient and preventing or improving at least one selected from the group consisting of skin wrinkles, reduced elasticity, lowered skin moisture content and skin aging / RTI >

In order to achieve the above objects, the present invention provides a pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays comprising Marian plum extract as an active ingredient.

In order to achieve still another object of the present invention, the present invention provides a method for preventing or improving at least one selected from the group consisting of skin wrinkles, skin elasticity, skin moisture content reduction, and skin aging, comprising Marian plum extract as an active ingredient Wherein said food composition is a food composition.

In order to achieve still another object of the present invention, the present invention provides a method for preventing or improving at least one selected from the group consisting of skin wrinkles, elasticity lowering, skin moisture content lowering and skin aging comprising the food composition according to the present invention And a health functional food composition.

In order to achieve still another object of the present invention, the present invention provides a method for preventing or improving at least one selected from the group consisting of skin wrinkles, skin elasticity, skin moisture content reduction, and skin aging, comprising Marian plum extract as an active ingredient A quasi-drug composition is provided.

Hereinafter, the present invention will be described in detail.

The present invention relates to a novel use of Marian plum extract, which comprises Marian plum extract as an active ingredient and is used for preventing or ameliorating at least one selected from the group consisting of skin wrinkles, reduced elasticity, lowered skin moisture content and skin aging And a cosmetic composition comprising the same.

The cosmetic composition according to the present invention is characterized in that it has an effect of promoting collagen synthesis, inhibiting collagen decomposition or promoting synthesis of a moisturizing factor.

The Marian Plum belongs to the Anacardiaceae family, which is an evergreen arboreous tree with a height of 30 meters. The stem skin is brown, long and cracked, and the base is flat, angular and has a characteristic of sagging downward. Leaves are alternate and monoploid, ovate to long oval or lanceolate, length (11 ~) 14 ~ 30 (~ 45) cm, width 4 ~ 5 ~ 8 (~ 13) cm, It is in the shape of a wedge or a wedge. The margin of the foliage is the leading edge, the margin of the leaf is acuminate at the edge and the petiole is 1 ~ 2.5cm in length. The inflorescence is acicular conifers with length of 4 ~ 12cm. Flowers are usually small with 4 water bodies. Calyxes are ovate, petals are long oval to obovate, 1.5 ~ 2.5mm long, 1mm wide and yellow or soon brown. The fruit is in the nucleus and has a circular or oval shape, 2.5-5cm in diameter, yellow to yellow with no hairs, flesh has a lot of juice, sweet or sour, has a slight terpene flavor and contains the nutrients shown in Table 1 below.

Nutritional component (per 100g) calorie 19.00kcal Main nutrient 11.30 g of carbohydrate, 0.02 g of fat, 0.04 g of protein, 0.15 g of dietary fiber, 0.02 g of ash, 86.60 g of moisture Inorganic salts Calcium 9.00 mg, iron 0.30 mg, phosphorus 4.00 mg Vitamins Vitamin C 100.00 mg, Vitamin B ₁ 0.11 mg, Vitamin B ₂ 0.05 mg, Vitamin B ₃ 0.50 mg, Alpha carotene 23.00 mg

In the present invention, marian plum refers to the flesh, leaves, or seeds of Bouea macrophylla and Bouea oppositifolia , which are subspecies in the Bow of Anacardiaceae do.

Thus, the Marian plum extract may be an extract of one or more plants selected from the group consisting of Boueemacro pilla or Boucheae opocytporia.

The extract of the present invention can be used in all parts of the Marian plum and is not limited to the extraction site, but Marian plum flesh can be preferably used. In order to produce an extract, it is not limited to the above-mentioned plant form, and the plant includes all those that have undergone processing such as drying.

The Marian plum extract may be extracted by a method known in the art, and the method is not particularly limited. Alternatively, commercially available extracts can be used.

Preferably, the Marian plum extract may be an extract obtained by extracting a part (flesh, leaf or seed) of Marian plum with at least one solvent selected from the group consisting of water, organic solvent, subcritical fluid and supercritical fluid , The organic solvent may be a polar organic solvent, a nonpolar organic solvent, or a mixture thereof. The polar organic solvent may be a lower alcohol having 1 to 6 carbon atoms, ethyl acetate or acetone, and the nonpolar organic solvent may be ether, chloroform, benzene, hexane or dichloromethane. For example, the lower alcohol having 1 to 6 carbon atoms may be methanol, ethanol, propanol, butanol or isopropanol.

In one embodiment, the Marian plum extract may be obtained by extraction under an ultra-high pressure superhigh pressure of 100 MPa or more. In addition, an extract obtained by directly pressing Marian plum or by separating and purifying from essential oil obtained by distillation can be used as Marian plum extract. In addition, the extract obtained by crushing the raw material of Marian plum and drying the juice may be used as a Marian plum extract. In addition, depending on the formulation, Marian plum weeds may be used instead of extracts. If necessary, it can be prepared by further adding filtration and concentration steps according to methods known in the art.

As can be seen in the following examples, Marian plum extract effectively inhibited collagenase and increased collagen production in human fibroblasts, exhibited skin aging, wrinkle and elasticity enhancement effects, The present invention relates to a cosmetic, a medicinal, a quasi-drug, a food or a health product for preventing and improving the skin aging, skin wrinkles, elasticity reduction and moisture reduction of skin due to increase in INV, LOR, TGM, FLG and CerS3 production involved in differentiation Can be used as an active ingredient of a functional food composition.

In the present invention, 'anti-aging effect of skin' refers to an effect of suppressing roughness, elasticity loss and wrinkling caused by aging naturally occurring as a result of aging or by photo-aging caused by ultraviolet rays (UV).

In the present invention, the term " wrinkle-reducing effect " means suppressing or inhibiting the generation of wrinkles on the skin by inhibiting collagenase and promoting collagen production, or alleviating wrinkles already formed.

In the present invention, the 'elasticity-enhancing effect' refers to an increase in elasticity to the skin, which inhibits collagenase and promotes collagen production to suppress or inhibit the loss of skin elasticity, It says.

In the present invention, the term 'skin moisturizing effect' refers to promoting the differentiation of keratinocytes to inhibit or inhibit reduction of moisture of the skin, increase the moisture content of the skin to smooth the surface of the skin, and impart luster It says.

The cosmetic composition of the present invention may be in the form of a general emulsified formulation and a solubilized formulation. For example, creams, essences, cosmetic creams, sprays, gels, packs, sunscreens, make-up bases, liquids such as lotions such as lotion, facial lotion, body lotion, A powder, a cleansing lotion, a makeup removing agent such as a cleansing oil, a cleaning agent such as a cleansing foam, a soap, a body wash and the like. The cosmetic composition may further comprise ingredients conventionally used according to the formulation.

In addition, the cosmetic composition may further contain, in addition to the Marian plum extract, a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Any of those commonly used in ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics ≪ RTI ID = 0.0 > cosmetic < / RTI >

The cosmetic composition may contain a relatively high concentration of the Marian plum extract in the case of a wash-off type cosmetic such as a makeup remover, a detergent, etc. in which the active ingredient remains on the skin in a short period of time. On the other hand, in the case of leave-on type cosmetics such as lotion, cream, essence and the like in which the active ingredient remains on the skin for a long period of time, a low concentration of the Marian plum extract is contained It may be possible. In one embodiment of the present invention, but not limited thereto, the composition may comprise the Marian plum extract in an amount of 0.001 wt% to 10 wt% (preferably 0.01 wt% to 5 wt%) based on the total composition weight have. When the composition of the present invention contains less than 0.001% by weight of the Marian plum extract, sufficient skin aging, skin wrinkles, reduced elasticity, and prevention or improvement of moisture in the skin can not be expected, In this case, it is intended to prevent an allergic reaction such as an unwanted reaction or a skin safety problem.

The cosmetic composition of the present invention may be provided as cosmetics having any one of formulations selected from the group consisting of cosmetics, essences, skins, lotions, creams, and packs containing Marian plum extract as an effective ingredient.

Examples of the cosmetics include a skin, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream moisturizer cream, a hand cream, a foundation, an essence, a nutrition essence, Foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.

In addition, the present invention provides a pharmaceutical composition for preventing or treating skin damage diseases caused by ultraviolet rays comprising Marian plum extract as an active ingredient. The pharmaceutical composition according to the present invention is characterized by having the effect of promoting collagen synthesis, inhibiting collagen decomposition or promoting the synthesis of a moisturizing factor.

In the present invention, the skin damage diseases caused by the ultraviolet rays may include skin erythema, photosensitivity, sunburn, skin edema, sunlight inflammation, skin photoaging, skin wrinkles, ≪ RTI ID = 0.0 > and / or < / RTI >

The composition may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may include a skin damage disease improving ingredient by known ultraviolet rays. If an additional UV-induced skin damaging disease improving ingredient is included, the effect of improving UV-induced skin damaging effects of the composition of the present invention may be further enhanced. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. The additional component may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition. For example, from 0.0001 wt% to 1 wt%, 0.0001 wt% to 0.1 wt%, 0.0001 wt% to 0.01 wt%, 0.0001 wt% to 0.001 wt%, 0.001 wt% to 10 wt%, 0.001 wt% to 1 wt% %, 0.001 wt% to 0.1 wt%, 0.001 wt% to 0.01 wt%, 0.01 wt% to 10 wt%, 0.01 wt% to 1 wt%, 0.01 wt% to 0.1 wt%, 0.1 wt% to 10 wt% 0.1% by weight to 1% by weight. The content range may be adjusted according to requirements such as skin safety, ease of formulation of the Marian plum extract, and the like.

In addition, the composition of the present invention may further comprise a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers may contain a variety of ingredients such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates, and the like.

The composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various forms of oral and parenteral administration at the time of clinical administration. In the case of formulation, a filler, , A binder, a wetting agent, a disintegrant, a surfactant, and the like.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used.

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

In the present invention, the term 'effective amount' means the amount of the extract capable of exhibiting an anti-aging effect of damaged skin, improving wrinkles, improving elasticity, or exhibiting a moisturizing effect. When the composition of the present invention contains an effective amount of the Marian plum extract, it is possible to provide an effect of preventing and improving skin damage diseases caused by ultraviolet rays. The effective amount of the Marian plum extract contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the extract is applied to the skin, and how long it remains on the skin. For example, when the composition is commercialized as a pharmaceutical formulation, the Marian plum extract may be contained at a higher concentration than the cosmetic product that is routinely applied to the skin. Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, and 1 to 6 mg / kg, ≪ / RTI >

The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

The pharmaceutical formulations of the present invention may include external preparation for skin.

When the Marian plum extract is used as an external preparation for skin, it may further contain at least one selected from the group consisting of a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, For example, water, ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin And any other ingredients used, such as those commonly used in the field of dermatology. The components can also be introduced in amounts commonly used in the field of dermatology.

When the Marian plum extract is provided as an external preparation for skin, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.

In addition, the present invention provides a food composition comprising Marian plum extract as an active ingredient and preventing or ameliorating at least one selected from the group consisting of skin wrinkles, reduced elasticity, reduced skin moisture content, and skin aging.

The present invention also provides a health functional food composition comprising the food composition, wherein at least one selected from the group consisting of skin wrinkles, reduced elasticity, reduced skin moisture content and skin aging is prevented or improved.

The food composition and the health functional food composition containing the same are characterized by having the effect of promoting collagen synthesis, inhibiting collagen decomposition or promoting synthesis of a moisturizing factor.

The food composition of the present invention includes all forms of functional foods, nutritional supplements, health foods, food additives and feeds, It is targeted for eating.

Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art. Common foods include but are not limited to beverages (including alcoholic beverages), fruits and processed foods (eg, canned fruits, jam, maamalade, etc.), fish, meat and processed foods (Eg butter, chewing), edible vegetable oil, margarine (such as corn oil, etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), juice, various drinks, cookies, , Vegetable protein, retort food, frozen food, various kinds of seasoning (for example, soybean paste, soy sauce, sauce etc.) by adding the above marian plum extract.

The nutritional supplement may be prepared by adding the above-mentioned Marian plum extract to capsules, tablets, rings and the like.

The health functional foods include, but are not limited to, for example, the above-mentioned Marian plum extract itself is prepared in the form of tea, juice, and drink to be liquefied, granulated, encapsulated, can do. In order to use the Marian plum extract in the form of a food additive, it may be prepared in the form of a powder or a concentrated liquid. The Marian plum extract may be prepared in the form of a composition by mixing it with a known active ingredient known to be effective for skin aging, skin wrinkles, reduced elasticity, and prevention or improvement of moisture in skin.

When the food composition of the present invention is used as a health beverage composition, the health beverage composition may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

Marian plum extract may be contained as an active ingredient of a food composition for preventing or improving skin aging, wrinkles, elasticity reduction or moisture content in the skin. The amount of Marian plum extract can be used as an active ingredient in skin aging, skin wrinkles, But the amount is preferably 0.01 to 100% by weight based on the total weight of the total composition. The food composition of the present invention may be prepared by mixing together with Marian plum extract together with other active ingredients known to be effective in preventing or inhibiting skin aging, wrinkles in skin, loss of elasticity and reduction in moisture content in the skin.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjusting agent, Glycerin, an alcohol or a carbonating agent, and the like. In addition, the health food of the present invention may contain natural fruit juice, fruit juice drink, or pulp for the production of vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention. Since the food preparation can be routinely ingested, it is very useful because high aging of the skin, wrinkles of the skin, reduction of the elasticity and prevention and improvement of the water content in the skin can be expected.

Also, the present invention provides a quasi-drug composition comprising Marian plum extract as an active ingredient and preventing or improving at least one selected from the group consisting of skin wrinkles, skin elasticity, skin moisture content reduction, and skin aging. The quasi-drug composition according to the present invention is characterized by having the effect of promoting collagen synthesis, inhibiting collagen decomposition or promoting the synthesis of a moisturizing factor.

The quasi-drug composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not affect the effect of the present invention, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, And the like.

Representative examples of acceptable carriers, excipients or diluents for the quasi-drug composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oils such as sodium carboxymethylcellulose, , Injectable ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.

When the Marian plum extract of the present invention is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may contain known skin elasticity enhancement, wrinkle improvement or moisturizing ingredients. When the skin elasticity enhancement, the wrinkle improvement or the moisturizing ingredient is included, the skin aging, skin wrinkles, elasticity reduction and prevention or improvement of the moisture content in the skin of the composition of the present invention may be further increased. When adding the above ingredients, skin safety, easiness of formulation, and stability of active ingredients can be taken into account according to the combined use. The quasi-drug composition may be a whitening ingredient known in the art, such as a substance inhibiting tyrosinase enzyme activity such as kojic acid, arbutin, hydroquinone, L-ascorbic acid; Retinoic acid, TGF, proteins from animal placenta, betulinic acid and chlorella extract, as skin elasticity, wrinkle or moisturizing ingredients known in the art; As anti-inflammatory ingredients known in the art, there are non-steroid based flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azene, hydrocortisone; And derivatives thereof, and various plant extracts. ≪ Desc / Clms Page number 2 > The additional ingredient may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content may be adjusted according to requirements such as skin safety and ease of formulation of Marian plum extract.

The quasi-drug composition of the present invention can be exemplified by a disinfectant cleaner, a shower foam, a softener solution, a wet tissue, a coating agent, and the like. The formulation method, dosage, usage method, And the like.

The Marian plum extract according to the present invention inhibits collagenolytic enzyme and promotes collagen production, thereby excelling in skin aging, wrinkle improvement and elasticity-enhancing activity and promoting differentiation of keratinocyte cells, , Medicines, quasi-drugs, food or health functional foods.

FIG. 1 shows the results of treatment of Bowman's macrofilarla flesh extract with Hs68 human dermal fibroblast and the amount of mRNA expression of COL1A1, COL3A1, COL4A1 and COL7A1. ( ^# p <0.01 vs control group, ^* p <0.05, ^** p <0.01 vs UVB treatment group)
FIG. 2 shows the results of treatment of the human fibroblast extract of Bowe ammacropila with Hs68 human dermal fibroblast, and the resulting protein expression amounts of MMP-1, MMP-2, MMP-3 and MMP-9. ( ^# p <0.01 vs control group, ^* p <0.05, ^** p <0.01 vs UVB treatment group)
FIG. 3 shows the results of treatment of the seed extract of Bowe ammacropila with Hs68 human dermal fibroblasts and the amount of mRNA expression of COL1A1, COL3A1, COL4A1 and COL7A1. ( ^# p <0.05, ^## p <0.01 vs control group; ^** p <0.01 vs UVB treatment group)
FIG. 4 is a graph showing the mRNA expression levels of MMP-1, MMP-2, MMP-3, and MMP-9 according to the treatment of the seed extract of Bowe ammacropila with Hs68 human dermal fibroblast. ( ^# p <0.01 vs control group, ^* p <0.05, ^** p <0.01 vs UVB treatment group)
FIG. 5 shows the results of treatment of Bowman's Macroplila leaf extract with Hs68 human dermal fibroblast and the expression of COL3A1 and MMP-1.
FIG. 6 is a graph showing the mRNA expression levels of INV, LOR, TGM, FLG, and CerS3 by treatment of Haeaa human keratinocyte with Bowe ammacropila pulp extract.
FIG. 7 shows the results of treatment of Haeaat human keratinocyte with Bowieamacro pilila seed extract and the mRNA expression levels of INV, LOR, TGM, FLG and CerS3.
FIG. 8 shows the results of treatment of Haeaat human keratinocyte with Bowe ammacropila leaf extract and the resulting mRNA expression levels of INV, LOR, TGM, FLG and CerS3.

Hereinafter, the present invention will be described in detail.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

[Example 1] Production of Boueema macrofila flesh extract

1) Preparation of ethanol extract of bouillarda macrofolia pulp

The dried bovine ammo pillar flesh was pulverized with a mixer, and 10 g of Ammachipila pulp sample in the pulverized bow was added to 100 mL of ethanol and extracted with stirring at 28 DEG C for 180 minutes. The extracted samples were filtered with filter paper of Whatman No. 2, and the filtered extract was concentrated with a vacuum rotary condenser to remove solvent components to obtain an extract of Bowieamacro pilila pulp.

2) Preparation of Methanol Extract of Bougueraceae Fructus Fruits

The dried bovine ammo pillar flesh was pulverized with a mixer, and 10 g of Ammacropila pulp sample in the pulverized bow was added to 100 mL of methanol and extracted with stirring at 28 DEG C for 180 minutes. The extracted sample was filtered with a filter paper No. 2 of Wattman, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component, thereby obtaining a methanol extract of Bowie ammacropila pulp.

3) Preparation of hot water extract of bovine ammo pillar flesh

The dried bovine ammo pillar flesh was pulverized with a mixer, and then 10 g of Ammachipila pulp sample in the pulverized bow was added to 100 mL of water and extracted with stirring at 82 DEG C for 180 minutes. The extracted sample was filtered with a filter paper No. 2 of Wattman, and the filtered extract was concentrated with a vacuum rotary condenser to remove solvent components, thereby obtaining a Boehmamaculpillar flesh extract of hot water.

4) Preparation of Bee Emma Crocodil Fructus hexane extract

The dried bloom was pulverized with a mixer, and 10 g of Ammacropila flesh sample in the pulverized bow was added to 100 mL of hexane and extracted with stirring at 28 DEG C for 180 minutes. The extracted samples were filtered with Wattmann filter paper No. 2, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent components, thereby obtaining a Bouilloma macrofilament pulp hexane extract.

5) Preparation of extracts of bovine amoecropyl fructose ethyl acetate

The dried bovine ammo pillar flesh was pulverized with a mixer, and 10 g of Ammacropila pulp sample in the pulverized bow was added to 10 mL of ethyl acetate and extracted with stirring at 28 DEG C for 180 minutes. The extracted sample was filtered with Wattman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent components, thereby obtaining a Boueemakroplila persimmon ethyl acetate extract.

6) Preparation of chloroform extract of bovine ammo pillar flesh

The dried bovine ammo pillar flesh was pulverized with a mixer, and 10 g of Ammacropila pulp sample in the pulverized bow was added to 100 mL of chloroform and extracted with stirring at 28 DEG C for 180 minutes. The extracted sample was filtered with Wattmann filter paper No. 2, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component, thereby obtaining a chloroform extract of Bauromacro pilila pulp.

7) Production of ultra-high pressure extract of Bougueramacro pilla flesh

The dried amber broth was pulverized with a mixer, and 1 g of Ammacropila pulp sample and 76 mL of 18% ethanol were added to the pulverized bowls. The bag was sealed in a polyethylene bag and sealed with a Frescal MFP- 7000; Mitsubishi Heavy Industries, Tokyo, Japan). Extraction pressure was 320 MPa and extraction time was 5 minutes. The extracted sample was filtered with a filter paper No. 2 of Wattman, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component, thereby obtaining a Boureum macrofilament pulp ultrahigh pressure extract.

8) Preparation of Supercritical Extract of Bougueramacro pilla Flesh

The dried bovine ammo pillar flesh was pulverized with a mixer, and 1 g of amakrofila pulp sample in the pulverized bow was charged into a sample cartridge. Then, a supercritical fluid extraction device (SFX 3560, Isco Inc., Lincoln, NE, USA ). Supercritical fluid extraction conditions were extraction pressure 20 MPa, extraction temperature 60 ℃, supercritical carbon dioxide flow rate 60 mL / min and extraction time 60 min. Upon completion of the supercritical fluid extraction, the supercritical fluid condition of the extraction system was lowered to release the supercritical fluid state to obtain the supercritical fluid extract of Amococcillus fructus in the bow.

9) Preparation of subcritical extract of Bougueraceae macrofillula pulp

The dried bloom was pulverized with a mixer, and 50 g of Ammacropila flesh in pulverized bowls was placed in a subcritical extraction device (Biovan, Gyeonggi, Korea) with 1 L of water and sealed . After sealing, the temperature of the reactor was raised to 200 DEG C, and when the temperature of the reactor reached 200 DEG C, the temperature was maintained for 20 minutes to extract. After 20 minutes, the extract was transferred to a storage tank to which cooling water was supplied, cooled rapidly to 30 ° C, and centrifuged at 3,600 rpm for 30 minutes to separate the floating residue. The solvent was completely removed by using a freeze drier (ilShin Lab Co. Ltd., Seoul, Korea) to obtain a subcritical extract of Bowe ammacropila pulp.

[Example 2] Preparation of a seed extract of Bowe ammacropila seeds

1) Preparation of ethanol extract of Bougueramacro pilila seeds

The ethanol extract of Bowieamacro pilila seeds was prepared in the same manner as in the preparation of the ethanol extract of Example 1-1, except that the bovine ammo pillar seeds were used.

2) Preparation of methanol extract of Bowieamacro pilila seeds

A methanol extract of Bowe ammacropila seeds was prepared in the same manner as in the preparation of the methanol extract of Example 1-2, except that the bovine ampicillat seeds were used.

3) Preparation of a hot water extract of Baueamacro pilila seeds

A bamboo ammo pillar seed hydrothermal extract was prepared in the same manner as in the production of the hot water extract of Example 1-3, except that the bovine ammo pillar seed was used.

4) Preparation of Amethylacrola pilla seed hexane extract

Bowieamacro pilila seeds hexane extract was prepared in the same manner as in the preparation of the hexane extract of Example 1-4, except that the B. amoecropila seed was used.

5) Preparation of Amethacroleum Seed Ethyl Acetate Extract of Boweae

Bowieamacro pilila seed ethyl acetate extract was prepared in the same manner as in the production of the ethyl acetate extract of Example 1-5, except that the B. amoecropila seed was used.

6) Preparation of chloroform extract of bovine amocclopila seeds

The same procedure as in the preparation of the chloroform extract of Example 1-6 was carried out except that amoecropea seeds were used in the Boweamacro pilola seed chloroform extract.

7) Manufacture of ultra-high pressure extract of Bougueramacro pilla seed

High pressure extract of Bowe ammacropila seed was prepared in the same manner as in the production method of the ultrahigh pressure extract of Example 1-7, except that the bovine ampicillat seeds were used.

8) Manufacture of Supercritical Extracts of Bouche Amakroplila Seeds

The supernatant extract of Bowe ammacropila seeds was prepared in the same manner as in the preparation of the supercritical extract of Example 1-8, except that the bovine ampicillin seeds were used.

9) Preparation of subcritical extract of Bougueramacro pilla seed

The same procedure as in the preparation of the subcritical extract of Example 1-9 was carried out except that the bovine ampicillat seeds were used.

[Example 3] Production of Bowe ammacropila leaf extract

1) Preparation of ethanol extract of Bouche ammacropila leaves

The ethanol extract of Bowe ammacropila leaves was prepared in the same manner as in the preparation of the ethanol extract of Example 1-1 except that amoecropea leaves were used.

2) Preparation of Methanol Extract of Leaf Macro Filler Leaf

The methanol extract of Bowe ammacropila leaf was prepared in the same manner as in the production of the methanol extract of Example 1-2, except that Amethrofila leaf was used.

3) Preparation of hot water extract of Amoecroplila leaf of Boweae

A bamboo ammo plilla leaf hot-water extract was prepared in the same manner as in the method for preparing the hot-water extract of Example 1-3, except that amoebacillus leaves were used.

4) Preparation of hexa extract of amoecrofila leaf

The extract of Bowe ammacropila leaf hexane was prepared in the same manner as in the preparation of the hexane extract of Example 1-4, except that Boume amacrophilla leaves were used.

5) Preparation of extracts of amoecrofila leaf ethyl acetate of Boweae

The extract of Bowie ammacropila leaves was prepared in the same manner as in the production of the ethyl acetate extract of Example 1-5, except that Amoecropea leaves were used.

6) Preparation of chloroform extract of Amoeco-pila leaf of Boweae

A chloroform extract of Bowe ammacropila leaves was prepared in the same manner as in the preparation of the chloroform extract of Example 1-6, except that amoebacillus leaves were used.

7) Preparation of ultra-high pressure extract of Bougueraceae macrofilament

High pressure extract of Bowe ammacropila leaf was prepared in the same manner as in the production method of the ultrahigh pressure extract of Example 1-7 except that amoecropea leaves were used.

8) Preparation of Supercritical Extract of Bougueraceae Macro Pillar Leaf

The supernatant extract of Bowe ammacropila leaf was prepared in the same manner as in the preparation of the supercritical extract of Example 1-8 except that amoecrofila leaves were used.

9) Preparation of subcritical extract of Bougueraceae macrofila leaf

The subcritical extract of Bowe ammacropila leaf was prepared in the same manner as in the preparation of the subcritical extract of Example 1-9 except that amoecrofila leaves were used.

[Example 4] Production of Boaia afociofolia pulp extract

1) Preparation of ethanol extract of bouillifolia porcine flesh

The ethanol extract of Boweia afociumporia was prepared in the same manner as in the preparation of the ethanol extract of Example 1-1, except that Boweia afociumporia flesh was used.

2) Preparation of hot water extract of bovine aflatoxinous folia

The bovine afforcia folia hot water extract was prepared in the same manner as in the method for preparing the hot-water extract of Example 1-3, except that the bovine affora planta was used.

3) Preparation of Supercritical Extract of Bouguerea afocia Folia

The supernatant extract of Boweia afociumpora was prepared in the same manner as in the preparation of the supercritical extract of Example 1-8, except that Boweia afociumporia flesh was used.

[Example 5] Preparation of seed extract of Bowiea afociumporia

1) Preparation of ethanol extract of Boweia afociumporia seeds

The ethanol extract of Boweia afociumporia seed was prepared in the same manner as in the preparation of the ethanol extract of Example 1-1 except that the seeds of Bouchea opportunioli were used.

2) Preparation of hot water extract of bouillifolia poria seed

A bovine afforcia seed hot water extract was prepared in the same manner as in the method for preparing the hot-water extract of Example 1-3, except that the seeds of Bouguerapoxifolia were used.

3) Preparation of Supernatant Extract of Bouchea afociumporia seeds

The supernatant extract of Boweia afociumporia was prepared in the same manner as in the preparation of the supercritical extract of Example 1-8, except that the seeds of Bouchea opportunioli were used.

[Example 6] Preparation of leaf extract of Bowiea afocytporia

1) Preparation of ethanol extract of bovine aflatoxinase

The ethanol extract of Boweia afociumporia leaves was prepared in the same manner as in the preparation of the ethanol extract of Example 1-1, except that Boweia afociumporia leaves were used.

2) Preparation of hot water extract of the leaves of Bougueraphos citrifolia

The extract of Boaia afociumporia leaves was prepared in the same manner as in the method of preparing the hot-water extract of Example 1-3, except that the leaves of Bouca epocitolia were used.

3) Preparation of Supercritical Extract of Boweia afociumporia leaf

The supernatant extract of Boweia afociumporia leaf was prepared in the same manner as in the preparation of the supercritical extract of Example 1-8, except that the Boucheae opocytporia leaves were used.

[Experimental Example 1] Effect of collagen synthesis of ethanol extract of Bowe ammacropila pulp

Hs68 human skin fibroblasts (ATCC, Manassas, Va., USA) were mixed with Dulbecco's modified Eagle's media (DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Hyclone, 2 x 10 &lt; ⁵ &gt; cells / well. After growing to 90%, the medium was removed, and DMEM (Hyclone) containing 10% FBS (Hyclone) was cultured in the same manner as in Example 1-1 except that the bovine ammo pillar pulp ethanol extract 25, 50 μg / mL and 0.01% dimethyl sulfoxide (DMSO) were dissolved and then treated with cells at various concentrations. The control group was treated with 0.01% DMSO instead of Bougueraceae macrofila ethanol extract. After 24 hours, the medium was removed and the plate was treated with 15 mJ / cm ² of ultraviolet light. DMEM (Hyclone) containing 10 μg / ml Amoacrophilia, 20 μg / ml and 0.01% DMSO was further treated for 24 hours . Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, Calif., USA). The isolated total RNA was quantitated using NanoDrop 1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA). The quantified 16 μL of RNA was amplified by PCR using a Reverse Transcriptase Premix (ELPIS-Biotech, Daejeon, Korea) and a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Woburn, Were synthesized as cDNA. (Collagen, type IV, alpha 1), COL7A1 (Collagen, type IV, alpha 1), COL4A1 (Collagen, type IV, alpha 1), and the following specific primers (Bioneer, Daejeon, Korea, COL1A1 PCR was performed 30 times at 95 ° C for 30 seconds, at 60 ° C for 1 minute, and at 72 ° C for 30 minutes with PCR premix (ELPIS-Biotech) using GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) . It was confirmed that the loading amount of mRNA was constant with GAPDH.

gene direction Sequence SEQ ID NO:   COL1A1 Forward 5'-GGGAGTTTCTCCTCGGGGTC-3 ' One Reverse 5'-GTCATCGCACAACACCTTGC-3 ' 2   COL3A1 Forward 5'-TGGTGCCCCTGGTCCTTGCT-3 ' 3 Reverse 5'-TACGGGGCAAAACCGCCAGC-3 ' 4   COL4A1 Forward 5'-TCCTGGCCTCCAGGGAATTA-3 ' 5 Reverse 5'-ATCAACAGATGGGGTGCCTG-3 ' 6   COL7A1 Forward 5'-ACCGTGAGCACCCTATTTGG-3 ' 7 Reverse 5'-CAACTGGTAGCGGGTCACAT-3 ' 8   GAPDH Forward 5'-CTCCTGTTCGACAGTCAGCC-3 ' 9 Reverse 5'-TCGCCCCACTTGATTTTGGA-3 ' 10

The PCR amplified cDNA was separated by electrophoresis on 1.5% agarose gel, and the intensity of the cDNA band was confirmed using G; BOX EF imaging system (Syngene, Cambridge, UK). The same experiment was performed three times in total, and the intensity of each cDNA band was quantitatively analyzed using Image J software (National Institutes of Health, NIH, Bethesda, MD, USA). When the cDNA band intensity in the group not treated with UVB was assumed to be 100%, the relative amount of cDNA expression in the sample treated group and the group treated with UVB was shown in FIG. 1 together with the cDNA band.

As shown in FIG. 1, the amounts of COL1A1, COL3A1, COL4A1, and COL7A1 mRNAs involved in collagen synthesis were significantly reduced ( ^## p <0.01) by UVB treatment in Hs68 human dermal fibroblasts, It was confirmed that the expression level of these extracts was significantly increased ( ^* p <0.05, ^** p <0.01) as a result of treatment with acaculolytic extract of ethanol extract. This means that the ethanol extract of the bouillarda macrofolila pulp of the present invention has an excellent ability to synthesize collagen in skin fibroblasts and can enhance skin elasticity.

[Experimental Example 2] Inhibitory effect of ethanol extract of Bowea macrofolia pulp on collagenase

Hs68 placed such that the 2 × 10 ⁵ cells / well in 6-well plates with human skin fibroblasts (ATCC) supplemented with 10% FBS with DMEM (Hyclone) containing the (Hyclone). After growing to 90%, the medium was removed and DMEM (Hyclone) containing 10% FBS (Hyclone) was cultured in the same manner as in Example 1-1 except that the ethanol extract of Bowe ammacropila 10% ethanol, 20 μg / mL and 0.01% DMSO After dissolving, cells were treated at each concentration. The control group was treated with 0.01% DMSO instead of Bougueraceae macrofila ethanol extract. After 24 hours, the medium was removed and the plate was treated with 15 mJ / cm ² of ultraviolet light. DMEM (Hyclone) containing 10 μg / ml Amoacrophilia, 20 μg / ml and 0.01% DMSO was further treated for 24 hours . And dissolved in NP-40 buffer (ELPIS-Biotech) containing Proteinase inhibitor cocktail. The cells dissolved in the buffer solution were transferred to a 1.5-mL tube and centrifuged at 13,000 rpm for 10 minutes to take only the supernatant. The supernatant was quantified using Bradford (Bio-Rad Laboratories Inc., Hercules, CA, USA) method. The quantified protein was boiled for 5 minutes, separated by electrophoresis on 10% SDS-PAGE, and the separated proteins were transferred to the nitrocellulose membrane. (Matrix metalloproteinase-1) primary antibody (Bioworld Technology, St. Louis Park, MN, USA) and MMP-1 (Matrix metalloproteinase-2), MMP-3 (BSA) diluted at a ratio of 1: 1000 with the primary antibody (Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA) and Matrix metalloproteinase-9 Lt; / RTI &gt; at room temperature. The primary antibody was reacted and the nitrocellulose membrane was washed three times for 10 minutes using Tris-buffered saline Tween 20 (TBST). After washing, secondary antibody (Bethyl Laboratories, Inc., Montgomery, TA, USA) with horseradish peroxidase conjugated to primary antibody was diluted to 1: 5000 in 2.5% BSA and incubated with nitrocellulose membrane for 2 hours at room temperature And washed three times for 10 minutes using TBST. Protein bands were developed using ECL western blotting detection reagents (Amersham, Tokyo, Japan) and protein bands were identified using G; BOX EF imaging system (Syngene, Cambridge, UK). The same experiment was performed three times in total, and each protein band intensity was quantitatively analyzed using Image J software (National Institutes of Health, NIH, Bethesda, MD, USA). When the protein band intensity in the group not treated with UVB was assumed to be 100%, the relative amount of protein expression in the sample treated group and the group treated with UVB was shown together with the band in FIG.

As shown in FIG. 2, it was confirmed that the amount of MMP-1, MMP-2, MMP-3 and MMP-9 protein expression was significantly increased ( ^## p <0.01) by treatment with UVB in Hs68 human dermal fibroblast . MMP-1, MMP-2, MMP-3, and MMP-9 protein levels increased by UVB treatment significantly ( ^* p <0.05, ^** p <0.01) . This means that the ethanol extract of the bouillardia macrofolila pulp of the present invention is excellent in the ability to inhibit collagenase in dermal fibroblast.

[Experimental Example 3] Collagen synthesis and collagenolytic enzyme inhibitory effect of Boueema macrofila flesh extract

In the same manner as in Experimental Example 1, the effect of collagen synthesis was measured at a concentration of 20 μg / mL in Experimental Example 2 at a concentration of 50 μg / mL of the bouillarda macrofolia extract prepared in Examples 1-2 to 1-9 After the collagenase inhibitory effect was measured in the same manner, the relative multiple of the UVB group was calculated.

As a result, as shown in Table 3, Bowieamacro pilla flesh extract significantly increased collagen synthesis and significantly inhibited collagenolytic enzyme compared to UVB treatment group. This means that the bouillarda macrofolica pulp extract of the present invention has excellent collagen-retaining ability of the skin and can enhance skin elasticity.

Example COL1A1 MMP-1 1-2 4.15 ^** 0.61 ^** 1-3 3.89 ^** 0.78 ^** 1-4 5.75 ^** 0.59 ^** 1-5 4.92 ^** 0.66 ^** 1-6 4.48 ^** 0.50 ^** 1-7 3.27 ^** 0.62 ^** 1-8 4.85 ^** 0.63 ^** 1-9 3.50 ^** 0.51 ^**

^** p <0.01 vs UVB treatment group

[Experimental Example 4] Collagen synthesis effect of ethanol extract of Bowieamacro pilila seed

The experiment was conducted in the same manner as in Experimental Example 1 by treating the Hs68 human skin fibroblasts at a concentration of 0.5 and 1 μg / mL with the ethanol extract of Bowe ammacropila seed prepared in Example 2-1.

As shown in FIG. 3, it was confirmed that the amount of COL1A1, COL3A1, COL4A1, and COL7A1 mRNA expression was significantly ( ^# p <0.05, ^## p <0.01) decreased by treatment with UVB in Hs68 human dermal fibroblasts, It was confirmed that the expression level of these extracts was significantly increased ( ^** p <0.01) by treatment with the acaculolytic ethanol extract. This means that the ethanol extract of Bowieamacro pilila seeds of the present invention is excellent in collagen synthesis ability in the skin fibroblast, which means that skin elasticity can be enhanced.

[Experimental Example 5] Collagenase inhibitory effect of ethanol extract of Bowieamacro pilila seeds

The experiment was conducted in the same manner as in Experimental Example 1 by treating the Hs68 human skin fibroblasts at a concentration of 0.5 and 1 μg / mL with the ethanol extract of Bowe ammacropila seed prepared in Example 2-1. At this time, PCR was carried out using the specific primers (Bioneer, Daejeon, Korea) shown in Table 4 below.

gene direction Sequence SEQ ID NO: GAPDH Forward 5'-CTCCTGTTCGACAGTCAGCC-3 ' 9 Reverse 5'-TCGCCCCACTTGATTTTGGA-3 10 MMP-1 Forward 5'-AAGTCAAGTTTGTGGCTTAT-3 ' 11 Reverse 5'-GACTCATGTCTCCTGTCTCT-3 ' 12 MMP-2 Forward 5'-CGCATCTGGGGCTTTAAACAT-3 ' 13 Reverse 5'-CCATTAGCGCCTCCATCGTA-3 ' 14 MMP-3 Forward 5'-GGCAAGACAGCAAGGCATAG-3 ' 15 Reverse 5'-ATCACCTCCAGAGTGTCGGA-3 ' 16 MMP-9 Forward 5'-TCTATGGTCCTCGCCCTGAA-3 ' 17 Reverse 5'-CATCGTCCACCGGACTCAAA-3 ' 18

As shown in FIG. 4, the mRNA expression levels of MMP-1, MMP-2, MMP-3 and MMP-9 were significantly increased ( ^## p <0.01) by treatment with UVB in Hs68 human dermal fibroblasts there was. MRNA expression of MMP-1, MMP-2, MMP-3 and MMP-9 by UVB was significantly ( ^* p <0.05, ^** p <0.01) Respectively. This means that the ethanol extract of Bowieamacro pilila seeds of the present invention is excellent in the ability to inhibit collagenase in dermal fibroblast.

[Experimental Example 6] Collagen synthesis and collagenase inhibitory effect of the seed extract of Boumamacro pilla

In the same manner as in Experimental Example 1, the effect of collagen synthesis was measured at a concentration of 1 μg / mL in Experimental Examples 4 and 5 at a concentration of 1 μg / mL using the above-described Bowenia macrofolia seed extract prepared in Examples 2-2 to 2-9 After the collagenase inhibitory effect was measured in the same manner, the relative multiple of the UVB group was calculated.

As shown in Table 5, Bowieamacro pilla seed extract significantly increased collagen synthesis and inhibited collagenolytic enzyme significantly compared to UVB treatment group. This means that the bouillarda macrofolia seed extract of the present invention has excellent collagen-retaining ability of the skin and can enhance skin elasticity.

Example COL1A1 MMP-1 1-2 3.01 ^** 0.28 ^** 1-3 2.67 ^** 0.39 ^** 1-4 3.41 ^** 0.32 ^** 1-5 2.98 ^** 0.39 ^** 1-6 3.55 ^** 0.40 ^** 1-7 3.38 ^** 0.25 ^** 1-8 4.25 ^** 0.42 ^** 1-9 3.67 ^** 0.38 ^**

^** p <0.01 vs UVB treatment group

[Experimental Example 7] Collagen synthesis and collagenolytic enzyme inhibitory effect of Bowe ammacropila leaf extract

The experiment was conducted in the same manner as in Experimental Example 1, except that the ethanol extract of Bowe ammacropila leaf prepared in Example 3-1 was treated with Hs68 human skin fibroblasts at a concentration of 0.5 and 1 μM. At this time, PCR was carried out using the specific primers (Bioneer, Daejeon, Korea) shown in Table 6 below.

gene direction Sequence SEQ ID NO: COL3A1 Forward 5'-TGGTGCCCCTGGTCCTTGCT-3 ' 3 Reverse 5'-TACGGGGCAAAACCGCCAGC-3 ' 4 GAPDH Forward 5'-CTCCTGTTCGACAGTCAGCC-3 ' 9 Reverse 5'-TCGCCCCACTTGATTTTGGA-3 ' 10 MMP-1 Forward 5'-ACCGTGAGCACCCTATTTGG-3 ' 19 Reverse 5'-CAACTGGTAGCGGGTCACAT-3 ' 20

As shown in FIG. 5, the expression of COL3A1 mRNA was increased and the amount of MMP-1 mRNA expression was decreased in Hs68 human dermal fibroblasts by treatment with the ethanol extract of Bowie ammo pellet leaf. This means that the ethanol extract of Bowe ammacropila leaves of the present invention has excellent collagen-retaining ability of the skin and can improve skin elasticity.

[Experimental Example 8] Moisturizing effect of ethanol extract of Bowieamacro pilla flesh

HaCaT was placed such that the 2 × 10 ⁵ cells / well in 6-well plates with human keratinocytes (ATCC) supplemented with 10% FBS with DMEM (Hyclone) containing the (Hyclone). After growing to 90%, the medium was removed, and 5. 10 μg / mL of ethanol extract of Bowe ammacropila pulp, prepared in Example 1-1, and 0.01% DMSO were dissolved in DMEM (Hyclone) Respectively. The control group was treated with 0.01% DMSO instead of Bougueraceae macrofila ethanol extract. After 24 hours, RT-PCR was carried out in the same manner as in Experimental Example 1 using the primers shown in Table 7 below.

gene direction Sequence SEQ ID NO: INV Forward 5'-GGGGCAGCTGAAGCACCTGG-3 ' 21 Reverse 5'-GAGACGGGCCACCTAGCGGA-3 ' 22 LOR Forward 5'-GGGTACCACGGAGGCGAAGGA-3 ' 23 Reverse 5'-ACTGAGGCACTGGGGTTGGGA-3 ' 24 TGM Forward 5'-CTTCCGTCTGCGCACCCCAG-3 ' 25 Reverse 5'-AGGCACAAACGACTGGCGCA-3 ' 26 FLG Forward 5'-AGTGCACTCAGGGGGCTCACA-3 ' 27 Reverse 5'-CCGGCTTGGCCGTAATGTGT-3 ' 28 CerS3 Forward 5'-GCGGTTAACAAGTGGTGAAACAG-3 ' 29 Reverse 5'-TCAGTCCACAAAAGGTGCCC-3 ' 30 GAPDH Forward 5'-TGACCTTGGCCAGGGGTGCT-3 ' 31 Reverse 5'-CCACCCGAGCCACATCGCTC-3 ' 32

As shown in FIG. 6, mRNAs of INV (involucrin), LOR (Loricrin), TGM (transglutaminase), FLG (filaggrin) and CerS3 (Ceramide Synthase 3) in HaCaT human keratinocyte It was confirmed that the expression level was increased. This means that the ethanol extract of bouillarda macrofolica pulp of the present invention is excellent in the ability to promote moisturization in keratinocytes.

[Experimental Example 9] Moisturizing effect of ethanol extract of Boweam macrophylla seed

The HaCaT human keratinocyte (ATCC) was treated at a concentration of 0.5 and 1 μg / mL with the ethanol extract of Bowe ammacropila seed prepared in Example 2-1, and the experiment was carried out in the same manner as in Experimental Example 8 .

As shown in FIG. 7, it was confirmed that mRNA expression levels of INV, LOR, TGM, FLG and CerS3 were increased in HaCaT human keratinocytes by treating the ethanol extract of Bowieamacro pilila seeds. This means that the ethanol extract of Bowieamacro pilila seed of the present invention is excellent in the ability to promote moisturization in keratinocytes.

[Experimental Example 10] Moisturizing effect of ethanol extract of Bowma ammacropila leaves

Hacca human keratinocyte (ATCC) was treated with the ethanol extract of Bowe ammacropila leaf prepared in Example 3-1 at a concentration of 0.5 and 1 μg / mL, and the same procedure as in Experimental Example 8 was carried out.

As shown in FIG. 8, it was confirmed that mRNA expression of INV, LOR, TGM, FLG and CerS3 was increased in HaCaT human keratinocytes by treatment with the ethanol extract of Bowie ammo pellet leaf. This means that the ethanol extract of bowel ammo pillar leaf of the present invention is excellent in the ability to promote moisturization in keratinocytes.

[Experimental example 11] Moisturizing effect of Boweam macrophila extract

The bouillarda macrofilament flesh extracts prepared in Examples 1-3, 1-5 and 1-8 were each prepared at a concentration of 10 μg / mL in Examples 2-3, 2-5, and 2-8 Bowe ammacropila seed extracts prepared in Examples 3-3, 3-5, and 3-8 at a concentration of 1 μg / mL, respectively, were cultured at a concentration of 1 μg / mL in human The cells were treated with keratinocytes (ATCC), and the experiment was carried out on FLG and CerS3 in the same manner as in Experimental Example 8. [ The intensity of each cDNA band was quantified using Image J software (National Institutes of Health, NIH, Bethesda, MD, USA). When the cDNA band intensity in the group not treated with UVB was 100%, the relative amount of cDNA expression was measured in the sample treated group and the group treated with UVB.

As shown in Table 8, the flesh, seed and leaf extracts of Bowieamacro pilola increased the expression levels of FLG and CerS3, which are skin moisturizing factors.

Example Relative mRNA expression level (% relative to control) FLG CerS3 1-3 184 231 1-5 156 194 1-8 201 220 2-3 265 237 2-5 282 251 2-8 239 221 3-3 238 195 3-5 210 238 3-8 189 212

[Experimental Example 12] Collagen synthesis and collagenolytic enzyme inhibitory effect of Bowiea opocytporia extract

The collagen synthesis effect was measured at a concentration of 20 μg / mL in the same manner as in Experimental Example 1 at the concentration of 50 μg / mL of the extract of Boweia opportunisporia prepared in Examples 4 to 6 , Respectively, and the relative abundance of the collagenase inhibitor was calculated for the UVB group.

As a result, as shown in Table 9, compared with the UVB treatment group, Bowiea afociumporia extract significantly increased collagen synthesis and significantly inhibited collagenolytic enzyme.

Example COL1A1 MMP-1 4-1 3.48 ^** 0.58 ^** 4-2 4.29 ^** 0.69 ^** 4-3 4.11 ^** 0.50 ^** 5-1 4.63 ^** 0.61 ^** 5-2 4.28 ^** 0.55 ^** 5-3 3.90 ^** 0.58 ^** 6-1 3.52 ^** 0.63 ^** 6-2 4.32 ^** 0.57 ^** 6-3 3.69 ^** 0.66 ^**

^** p <0.01 vs UVB treatment group

[Experimental Example 13] Moisturizing effect of Bowiea opocytporia extract

The borealophosphatidiae extracts prepared in Example 4 were respectively added at a concentration of 10 [mu] g / mL and the borealophocityporia seed extract prepared in Example 5 at a concentration of 1 [mu] g / mL (ATCC) were treated at a concentration of 1 μg / mL, respectively, and the FLG and CerS3 were tested in the same manner as in Experimental Example 8 . The intensity of each cDNA band was quantified using Image J software (National Institutes of Health, NIH, Bethesda, MD, USA). When the cDNA band intensity in the group not treated with UVB was 100%, the relative amount of cDNA expression was measured in the sample treated group and the group treated with UVB.

As shown in Table 10, the flesh, seed and leaf extracts of Boweia afociumporia increased the amount of skin moisturizing factors FLG and CerS3.

Example Relative mRNA expression level (% relative to control) FLG CerS3 4-1 216 186 4-2 180 190 4-3 254 182 5-1 221 229 5-2 269 240 5-3 219 237 6-1 198 202 6-2 202 220 6-3 230 219

Hereinafter, examples of production of cosmetics, foods, and medicines for skin aging and moisturizing, comprising Marian plum extract according to the present invention as an active ingredient, will be described, but the present invention is not limited thereto but is specifically described. The cosmetics, food, and pharmaceutical compositions of Preparations 1 to 3 were prepared according to the conventional methods according to the following composition components and composition ratios with Marian plum extract having excellent skin aging and moisturizing activity.

[Manufacturing Example 1] Cosmetics

1) Nourishing lotion (milk lotion)

The Marian plum extracts of Examples 1 to 6 were prepared according to a conventional method with the ingredients and contents shown in Table 11 below.

Compounding ingredient Production Example 1-1
(weight%) Marian plum extract 2.0 Squalane 5.0 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 1.5 Liquid paraffin 0.5 Caprylic / capric triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water to 100

2) Flexible lotion (skin lotion)

The Marian plum extracts of Examples 1 to 6 were prepared according to a conventional method with the ingredients and contents shown in Table 12 below.

Compounding ingredient Production Example 1-2
(weight%) Marian plum extract 2.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonyl phenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, fragrance Suitable amount Purified water to 100

3) Nourishing cream

The nutritional creams were prepared according to a conventional method with the ingredients and contents of the Marian plum extracts of Examples 1 to 6 shown in the following Table 13.

Compounding ingredient Production Example 1-3
(weight%) Marian plum extract 2.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG60 hardened castor oil 2.0 Liquid paraffin 10 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 antiseptic Suitable amount Pigment Suitable amount Spices Suitable amount Purified water to 100

4) Massage cream

The Marian plum extracts of Examples 1 to 6 were prepared in accordance with a conventional method with the ingredients and contents shown in Table 14 below.

Compounding ingredient Production Example 1-4
(weight%) Marian plum extract 1.0 Wax 10.0 Polysorbate 60 1.5 PEG 60 hardened castor oil 2.0 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water to 100

5) Pack

The Marian plum extracts of Examples 1 to 6 were packed according to a conventional method with the ingredients and contents shown in Table 15 below.

Compounding ingredient Production Example 1-5
(weight%) Marian plum extract 1.0 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonyl phenyl ether 0.3 Polysorbate 60 0.3 Preservative, coloring, fragrance Suitable amount Purified water to 100

6) Gel

The Marian plum extracts of Examples 1 to 6 were prepared according to a conventional method with the ingredients and contents shown in Table 16 below.

Compounding ingredient Production Example 1-6
(weight%) Marian plum extract 0.5 Ethylenediamine sodium acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hardened castor oil 0.5 Triethanolamine 0.3 Preservative, coloring, fragrance Suitable amount Purified water to 100

[Production Example 2]

1) Manufacture of health food

The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. The results are shown in Table 1. Example 1 Marian plum extract 1000 mg, vitamin A acetate 70 mg, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, 10 mg, nicotinamide 1.7 mg, folic acid 50 mg, calcium pantothenate 0.5 mg, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium monophosphate 15 mg, dicalcium phosphate 55 mg, potassium citrate 90 mg, calcium carbonate 100 mg, magnesium chloride 24.8 mg, and the compounding ratio may be optionally changed. The above ingredients are mixed according to a conventional method for producing healthy foods, and then granules are prepared And can be used in the manufacture of a health food composition according to a conventional method.

2) Manufacture of health drinks

Purified water was added to 1000 mg of the Marian plum extract of Examples 1 to 6, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of the plum concentrate and 1 g of taurine, and the above components were mixed according to the general 900 mL ordinary health drink manufacturing method Then, after stirring and heating at 85 DEG C for about 1 hour, the solution thus prepared is filtered and sterilized in a 2 L container to be sterilized by sterilization, and then stored in a refrigerator for use in the manufacture of a health beverage composition.

3) Chewing gum

Chewing gum was prepared by combining 20% by weight of a gum base, 76.9% by weight of sugar, 1% by weight of fragrance and 2% by weight of water and 0.1% by weight of the Marian plum extract of Examples 1 to 6.

4) Candy

Candies were prepared by mixing 60% by weight of sugar, 39.8% by weight of starch syrup, 0.1% by weight of fragrance and 0.1% by weight of the Marian plum extract of Examples 1 to 6 by a conventional method.

5) Biscuits

A mixture of 0.75% by weight of sodium chloride, 0.78% by weight of glucose, 11.78% by weight of palm shortening, 1.54% by weight of ammonium, 0.17% by weight of sodium bicarbonate and 0.16% by weight of sodium bisulfite, 25.59% by weight of Grade I, 22.22% 1.45 wt% of rice flour, 0.0001 wt% of vitamin B, 0.04 wt% of milk fractions, 20.6998 wt% of water, 1.16 wt% of whole milk powder, 0.29 wt% of replacement milk powder, 0.03 wt% of calcium phosphate, 0.29 wt% 7.27% by weight of milk and 1% by weight of the Marian plum extract of Examples 1 to 6 were blended to prepare biscuits by a conventional method.

[Preparation Example 3]

1) Powder

50 mg of the Marian plum extract of Examples 1 to 6 and 2 g of crystalline cellulose were mixed and filled in an airtight cell according to a conventional acid preparation method to prepare a powder.

2) Tablets

After mixing 50 mg of the Marian plum extract of Examples 1 to 6, 400 mg of crystalline cellulose and 5 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet preparation method.

3) Capsules

30 mg of the Marian plum extract of Examples 1 to 6, 100 mg of whey protein, 400 mg of crystalline cellulose and 6 mg of magnesium stearate were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

As described above, the Marian plum extract according to the present invention can inhibit collagenase, promote collagen production, improve skin aging, promote differentiation of keratinocytes and improve skin moisturization, The present invention further provides a composition for promoting collagen synthesis, which comprises an extract as an active ingredient. The composition further has a skin aging effect, a wrinkle of the skin, a decrease in elasticity, , Quasi-drugs, foods or health functional foods.

&Lt; 110 > AAT Costech Co., Ltd. <120> Composition for skin comprising anti-aging or moisturizing          extract of marian plum <130> NP18-0031 <150> KR 2017/0053999 <151> 2017-04-26 <160> 32 <170> KoPatentin 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL1A1 forward primer <400> 1 gggagtttct cctcggggtc 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL1A1 reverse primer <400> 2 gtcatcgcac aacaccttgc 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL3A1 forward primer <400> 3 tggtgcccct ggtccttgct 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL3A1 reverse primer <400> 4 tacggggcaa aaccgccagc 20 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL4A1 forward primer <400> 5 tcctggcctc cagggaatta 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL4A1 reverse primer <400> 6 atcaacagat ggggtgcctg 20 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL7A1 forward primer <400> 7 accgtgagca ccctatttgg 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> COL7A1 reverse primer <400> 8 caactggtag cgggtcacat 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH forward primer <400> 9 ctcctgttcg acagtcagcc 20 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH reverse primer <400> 10 tcgccccact tgattttgga 20 <210> 11 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-1 forward primer <400> 11 aagtcaagtt tgtggcttat 20 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-1 reverse primer <400> 12 gactcatgtc tcctgtctct 20 <210> 13 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> MMP-2 forward primer <400> 13 cgcatctggg gctttaaaca t 21 <210> 14 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-2 reverse primer <400> 14 ccattagcgc ctccatcgta 20 <210> 15 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-3 forward primer <400> 15 ggcaagacag caaggcatag 20 <210> 16 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-3 reverse primer <400> 16 atcacctcca gagtgtcgga 20 <210> 17 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-9 forward primer <400> 17 tctatggtcc tcgccctgaa 20 <210> 18 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-9 reverse primer <400> 18 catcgtccac cggactcaaa 20 <210> 19 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-1 forward primer <400> 19 accgtgagca ccctatttgg 20 <210> 20 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-1 reverse primer <400> 20 caactggtag cgggtcacat 20 <210> 21 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> INV forward primer <400> 21 ggggcagctg aagcacctgg 20 <210> 22 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> INV reverse primer <400> 22 gagacgggcc acctagcgga 20 <210> 23 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> LOR forward primer <400> 23 gggtaccacg gaggcgaagg a 21 <210> 24 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> LOR reverse primer <400> 24 actgaggcac tggggttggg a 21 <210> 25 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TGM forward primer <400> 25 cttccgtctg cgcaccccag 20 <210> 26 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TGM reverse primer <400> 26 aggcacaaac gactggcgca 20 <210> 27 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> FLG forward primer <400> 27 agtgcactca gggggctcac a 21 <210> 28 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FLG reverse primer <400> 28 ccggcttggc cgtaatgtgt 20 <210> 29 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> CerS3 forward primer <400> 29 gcggttaaca agtggtgaaa cag 23 <210> 30 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> CerS3 reverse primer <400> 30 tcagtccaca aaaggtgccc 20 <210> 31 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH forward primer <400> 31 tgaccttggc caggggtgct 20 <210> 32 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH reverse primer <400> 32 ccacccgagc cacatcgctc 20

Claims (12)

The cosmetic composition according to any one of claims 1 to 3, wherein the extract contains marijuana extract as an active ingredient and prevents or improves at least one selected from the group consisting of skin wrinkles, reduced elasticity, reduced skin moisture content and skin aging.
The method according to claim 1,
Wherein the composition has an effect of promoting collagen synthesis, inhibiting collagen decomposition or promoting synthesis of a moisturizing factor.
The method according to claim 1,
Wherein the Marian plum extract is extracted from at least one plant selected from the group consisting of Bouea macrophylla and Bouea oppositifolia .
The method according to claim 1,
Wherein the Marian plum extract is extracted with at least one solvent selected from the group consisting of water, organic solvents of 1 to 6 carbon atoms, subcritical and supercritical.
5. The method of claim 4,
The organic solvent having 1 to 6 carbon atoms may be selected from the group consisting of alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, wherein the cosmetic composition is at least one selected from the group consisting of hexane, cyclohexane, and petroleum ether.
The method according to claim 1,
Wherein the Marian plum extract is obtained by extracting Marian plum under an ultra-high pressure of 100 MPa or more.
A pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays comprising marijuana extract as an active ingredient.
8. The method of claim 7,
The skin damage diseases caused by ultraviolet rays are selected from the group consisting of erythema, photosensitivity, sunburn, skin edema, sunlight inflammation, skin photoaging, skin wrinkles, elasticity degradation, skin moisture loss, skin capillary dilatation, &Lt; / RTI &gt;
Wherein the composition contains marijuana extract as an active ingredient and prevents or improves at least one selected from the group consisting of skin wrinkles, reduced elasticity, lowered skin moisture content, and skin aging.
10. The method of claim 9,
Wherein the composition has an effect of promoting collagen synthesis, inhibiting collagen decomposition or promoting the synthesis of a moisturizing factor.
A health functional food composition comprising the food composition according to claim 9, wherein at least one selected from the group consisting of skin wrinkles, reduced elasticity, reduced skin moisture content and skin aging is prevented or improved.
Wherein the extract contains marijuana extract as an active ingredient and prevents or improves at least one selected from the group consisting of skin wrinkles, reduced elasticity, reduced skin moisture content, and aging of the skin.

Images